Ovid Therapeutics OVID Income Statement (2016-2026)

NASDAQ OVID
$2.80 +0.02 (+0.72%)
At close: Sep 4, 2026 · 4:00 PM EDT
Reported Financials

Ovid Therapeutics Quarterly Income Statement

Periods 42 quarters
Latest Jun 2026

Ovid Therapeutics reported revenue of $0.73M and net income of -$15.01M for the quarter ended Jun 2026, down 88.3% year over year. This income statement covers 42 quarters of results from Mar 2016 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue
1.45M0.01M0.05M0.07M0.07M0.11M0.14M0.15M0.17M0.17M0.08M0.13M6.27M0.13M0.72M0.73M
Operating items
Research & DevelopmentR&D
4.92M12.30M7.83M6.05M5.18M5.56M6.62M6.00M5.33M10.64M10.40M12.58M7.86M5.92M6.66M6.46M5.87M6.59M11.18M9.96M
Selling, General & AdministrativeSG&A
6.76M8.26M9.88M8.26M7.63M6.66M8.34M8.25M6.80M7.69M7.17M8.10M5.54M4.88M6.02M4.88M6.79M6.42M6.67M6.47M
Other Operating ExpensesOther Opex
0.00M0.00M0.21M-0.28M0.84M-0.00M
Operating ExpensesOpex
11.68M26.35M17.71M14.30M12.81M12.22M14.96M14.25M12.14M18.33M17.57M20.69M13.40M10.80M12.68M11.35M12.65M13.01M17.85M16.43M
Operating IncomeOp. Inc
-11.68M-26.35M-16.27M-14.30M-12.80M-12.17M-14.89M-14.17M-12.03M-18.19M-17.42M-20.52M-13.23M-10.72M-12.55M-5.07M-12.52M-12.29M-17.85M-15.70M
EBIT
-11.68M-26.35M-16.27M-14.30M-12.80M-12.17M-14.89M-14.17M-12.03M-18.19M-17.42M-20.52M-13.23M-10.72M-12.55M-5.07M-12.52M-12.29M-17.85M-15.70M
Non-operating items
Interest & Investment IncomeInt & Inv Inc
Other Non Operating IncomeOther Non Op Inc.
0.21M-0.28M0.84M0.67M1.54M1.76M0.78M2.87M5.72M29.04M-0.78M1.47M2.31M0.39M0.36M21.96M0.86M0.69M
Non Operating IncomeNon Op. Inc.
Net income details
EBT
-11.68M-26.35M-16.06M-14.59M-11.97M-11.50M-13.36M-12.41M-11.25M-15.32M-11.69M8.52M-14.01M-9.25M-10.23M-4.68M-12.16M9.66M-16.99M-15.01M
Tax ProvisionsTaxes
-0.29M-0.35M0.05M
Profit After TaxPAT
-11.38M-26.00M-16.11M-14.59M-11.97M-11.50M-13.36M-12.41M-11.25M-15.32M-11.69M8.52M-14.01M-9.25M-10.23M-4.68M-12.20M9.69M-16.99M-15.01M
Income from Continuing OperationsIncome (Continuing)
-11.38M-26.00M-16.11M-14.59M-11.97M-11.50M-13.36M-12.41M-11.25M-15.32M-11.69M8.52M-14.01M-9.25M-10.23M-4.68M-12.16M9.66M-16.99M-15.01M
Consolidated Net IncomeConsol Net Inc.
-11.38M-26.00M-16.11M-14.59M-11.97M-11.50M-13.36M-12.41M-11.25M-15.32M-11.69M8.52M-14.01M-9.25M-10.23M-4.68M-12.16M9.66M-16.99M-15.01M
Income towards Parent CompanyParent Net Inc
-11.38M-26.00M-16.11M-14.59M-11.97M-11.50M-13.36M-12.41M-11.25M-15.32M-11.69M8.52M-14.01M-9.25M-10.23M-4.68M-12.16M9.66M-16.99M-15.01M
Net Income towards Common StockholdersNet Income
-11.38M-26.00M-16.11M-14.59M-11.97M-11.50M-13.36M-12.41M-11.25M-15.32M-11.69M8.52M-14.01M-9.25M-10.23M-4.68M-12.16M9.66M-16.99M-15.01M
Additional items
EPS (Basic)
-0.17-0.39-0.23-0.21-0.17-0.16-0.19-0.18-0.16-0.22-0.170.12-0.20-0.13-0.14-0.07-0.170.13-0.12-0.08
EPS (Diluted)
-0.17-0.38-0.23-0.21-0.17-0.16-0.19-0.18-0.16-0.22-0.170.12-0.20-0.13-0.14-0.07-0.170.13-0.12-0.08
Shares Outstanding
67.93M67.48M70.35M70.39M70.43M70.42M70.49M70.53M70.62M70.58M70.72M70.92M70.98M70.91M71.05M71.11M71.11M73.74M136.17M197.45M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
67.93M68.07M70.35M70.39M70.43M70.42M70.49M70.53M70.62M70.58M70.72M71.20M70.98M70.91M71.05M71.11M71.11M73.74M136.17M197.45M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
68.02M70.36M70.42M70.42M70.47M70.47M70.49M70.60M70.68M70.69M70.78M70.97M71.01M71.01M71.11M71.11M71.15M73.74M136.17M184.76M
EBITDA
-11.68M-26.35M-16.27M-14.30M-12.80M-12.17M-14.89M-14.17M-12.03M-18.19M-17.42M-20.52M-13.23M-10.72M-12.55M-5.07M-12.52M-12.29M-17.85M-15.70M
Tax Rate
2.52%1.33%-0.31%